Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib C. Leitner, R. von Moos,

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer Kristin N.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor Song Xu, Qingchun Zhao, Sen Wei, Yi.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Lungs on Fire Journal of Thoracic Oncology

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

ALK FISH and IHC: You Cannot Have One without the Other

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

MET-Mutated NSCLC with Major Response to Crizotinib

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

The Moth-Eaten Lung Journal of Thoracic Oncology

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma Christine Cordova, MD, Andrew S. Chi,

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Metastatic Angiosarcoma Arising From the Right Atrium: Unusual Presentation and Excellent Response to Treatment in a Young Patient Martin Fehr, MD, Max.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

A Severe Photosensitivity Dermatitis Caused by Crizotinib

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Evaluating Cryoablation of Metastatic Lung Tumors in Patients—Safety and Efficacy The ECLIPSE Trial—Interim Analysis at 1 Year Thierry de Baere, MD,

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Vamsidhar Velcheti, MD, Manmeet Ahluwalia, MD

Cerebral Nocardiosis Mimicking Multiple Brain Metastases in a Patient with Locally Advanced Non–Small-Cell Lung Cancer Cathy Voide, MD, Stefan Zimmermann,

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement Denis Maillet, MD, Isabelle Martel-Lafay,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Rachel Benamore, MB BChir, MRCP, FRCR, Frances A

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

In This Issue Journal of Thoracic Oncology

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

European Lung Cancer Conference (ELCC) 2016 Organisation

Recurrent Primary Synovial Sarcoma of the Chest Wall

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Successful AZD9291 Therapy Based on Circulating T790M

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

David Garfield, MD Journal of Thoracic Oncology

Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report Katarzyna Dziadziuszko, MD, Edyta Szurowska, MD, PhD, Joanna.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Adding Bevacizumab to Chemotherapy Effectively Control Radioresistant Brain Metastases in ALK-Positive Lung Adenocarcinoma Yu-Li Su, MD Journal of Thoracic Oncology Volume 10, Issue 4, Pages e21-e22 (April 2015) DOI: 10.1097/JTO.0000000000000449 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Representative image series from initial diagnosis (A–C), intracranial progression (D–F), and disease regression (G–I). A, A spiculated Left lower lung (LLL) mass in nonenhanced CT. B and C, T1 postgadolinium showed multiple intracranial metastases over right vermis, left posterior temporal, and frontal area. D, Left lower lung (LLL) tumor regressed after pemetrexed/cisplatin treatment. E and F, T2 FLAIR showed enlarged brain metastases with significant perifocal edema. G–I, Regression of primary tumor as well as intracranial metastases after adding bevacizumab to pemetrexed/cisplatin. CT, computed tomography. Journal of Thoracic Oncology 2015 10, e21-e22DOI: (10.1097/JTO.0000000000000449) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions